A total of 1,348 poxviral injections were given in 215 patients. No contact transmission, inadvertent inoculati on, or any serious adverse events (AEs) related to vaccinia were observed. Below is the summary of proportion of vaccine administrations associated with specific AEs. These data demonstrate a favorable safety profile of the poxviral vaccines at a broad ran ge of doses, routes of administration, in combination with other treatments, and in various tumor types. Clinical trial information: NCT00060528, NCT00096551, NCT00088413, NCT00081848, NCT00113984, NCT00450619, NCT00450463. Table 3. Safety of poxviral vaccines: NCI experience 24 AEs Grade 2 Grade 3 Grade 4 % of injections associate with an AE Injection -site reaction 454 0 0 25.3 Injection -site cellulitis 0 2 0 0.1 Fever 22 2 0 1.3 General symptoms (fatigue, myalgia, rash, etc.) 53 7 0 3.3 Respiratory AEs (dyspnea, etc.) 4 2 0 0.3 Gastrointestinal AEs (nausea, etc.) 13 3 0 0.9 Neurologic AEs (headache, etc.) 9 2 0 0.6 Hypotension 3 0 0 0.2 Myocardial infarction 0 0 1* 0.1 Atrial fibrillation 1 0 0 0.1 21 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential AEs Grade 2 Grade 3 Grade 4 % of injections associate with an AE Cytopenia 6 1 0 0.4 TTP 0 0 1* 0.1 Lab abnormalities 7 0 0 0.4 Total 572 19 2 33.1 * One patient experienced multiple AEs associated with myocardial infarction and thrombotic thrombocytopenic purpura (TTP). 1.2.12 Modifi ed vaccinia Ankara (MVA) Despite the desirab le features of poxviruses, replication-competent viruses like vaccinia should not be administered to severely immunocompromised patients.